Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double‐blind, placebo‐controlled trial

Abstract

Recombinant relaxin was not significantly better than placebo in improving the total skin score or pulmonary function or in reducing functional disability in patients with dcSSc. In addition, relaxin was associated with serious renal adverse events, the majority of which occurred after stopping the infusion. If relaxin is used therapeutically for any conditions other than scleroderma, close monitoring of blood pressure and renal function must be performed.